Abstract
Recently, a streptococcal preparation, OK-432 has been used successfully as an immunopotentiator for immunotherapy in patients with malignant tumors in Japan. In this paper, we report that the administration of OK-432 augments the cytotoxic activity of peripheral blood lymphoid cells against a natural killer (NK) cell-sensitive erythroleukemic cell line, K562, in tumor patients. In patients before or after surgery, sufficient amounts of OK-432 strongly augmented the cytotoxic activity within 3 days after the initial administration of OK-432. Thereafter the levels of cytotoxicity declined rapidly. The administration of a lower dose of OK-432 gave a lower increase in cytotoxicity. Enhanced cytotoxicity occurred with the reintroduction of OK-432 but remained at lower levels of activity. Characterization and fractionation of OK-432-induced effector cells revealed that the augmented cytotoxicity seemed to be carried mainly by NK cells. A low titer of interferon was detected in 3 of 10 patients within 72 hr after the first inoculation of the agent. Furthermore, we discuss the potency of OK-432 for the induction of interferon in detail.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Okamoto H, Shoin S, Kashimura S, Shimizu R: Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jap J Microbiol 11:323–336, 1976
Kimura I, Ohnosi T, Yasuhara S, Sugiyama M, Urabe Y, Fujii M, Machida K: Immunochemotherapy in human lung cancer using the streptococcal agent OK-432. Cancer 37:2201–2203, 1976
Hattori T, Niimoto M, Yamagata S, Tohge T: Clinical studies on streptococcal preparation (OK-432). Combined with mitomycin-c, 5-FU and cytosine arabinoside in advanced cancer patients. Jap J Surg 5:133–138, 1975
Morton D, Goodnight J: Cancer immunology and immunotherapy.In Cancer Treatment, CM Haskell (ed). London, W. B. Saunders, 1980, p 124–155
Israël L, Edelstein R: Non specific immunostimulation with corynebacterium parvum in human cancer.In Immunological Aspects of Neoplasia. London, W. B. Saunders, 1974, p 124
Eppinger-Helft M, Pavlovsky S, Hidalgo G, Muriel FS, Suarez A, Gray G, Russo C, Santos M, Macch A, Lein J: Chemoimmunotherapy with corynebacterium parvum in acute myelocytic leukemia. Cancer 45:280–284, 1980
Tripodi D, Parkes LC, Brugmans J: Drug-induced restoration of cutaneous delayed hypersensitivity in allergic patients with cancer. N Engl J Med 289:354–357, 1973
Hirshaut Y, Piusky CM, Frydecka I, Wanebo HJ, Passe S, Mike V, Oettgen HF: Effect on short-term levamisole therapy on delayed hypersensitivity. Cancer 45:362–366, 1980
Uchida A, Hoshino T: Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte population and phytomitogen responsivenessin vitro. Cancer 45:476–483, 1980
Ohta T: Experimental anticancer studies VI. Experiments on the influence of living A group hemolytic streptococci and several other species of microorganisms on the invasion power of Ehrlich carcinoma cells to mice. Jap J Exp Med 27:107–116, 1979
Kaibara N, Ikeda T, Hattori T, Inokuchi K: Effectiveness of treatment using a streptococcal preparation (PC-B-45) and mitomycin C on transplanted mouse tumor. Gann 63:387–390, 1972
Sakurai Y, Tsukagoshi S, Satoh H, Akiba T, Suzuki S, Takagaki Y: Tumour inhibitory effect of a streptococcal preparation (NSC-B 116209). Cancer Chemother Rep 56:9–17, 1972
Ono T, Kurata S, Wakabayashi K, Sugawara Y, Saitoh M, Ogawa H: Inhibitory effect of a streptococcal preparation (OK-432) on the nucleic acid synthesis in tumour cellsin vitro. Gann 64:59–69, 1973
Ishii Y, Yamaoka H, Toh K, Kikuchi K: Inhibition of tumor growthin vivo andin vitro by macrophages from rats treated with a streptococcal preparation, OK-432. Gann 67:115–119, 1976
Einhorn S, Blomgren H, Strander H: Interferon and spontaneous cytotoxicity in man. I. Enhancement of the spontaneous cytotoxicity of peripheral lymphocytes by human leukocyte interferon. Int J Cancer 22:405–412, 1978
Trinchieri G, Santoli D: Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 147:1314–1333, 1978
Gidland M, Örn A, Wigzell H: Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 273:759–761, 1978
Welsh DM Jr: Mouse natural killer cells induction specificity, and function. J Immunol 121:1631–1635, 1978
Oshimi K, Kano S, Takaku F, Okumura K: Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Natl Cancer Inst 65:1265–1270, 1980
Madsen M, Johnsen HE: A methodological study of E-rosette formation using AET-treated sheep red cells. J Immunol Methods 27:61–74, 1979
Oshimi K, Gonda N, Sumiya M, Kano S: Effects of corticosteroids on natural killer cell activity in systemic lupus erythematosus. Clin Exp Immunol 40:83–88, 1980
Wakasugi H, Miyata M, Morioka Y, Oshimi K, Nakano M: Natural killer cell activity in patients with malignant diseases. Igaku no Ayumi 113:256–260, 1980 (Jp.)
Betzler M, Fled HD, Geinheiner V, Herferth Ch: Natural killer cell activity in patients with malignant tumors before and after surgical treatment. Abstracts of the 5th Annual Meeting of the Medical Oncology Society, 1979, p 7
Huddlestone JR, Merigan TC, Oldstone MBA: Induction and kinetics of natural killer cells in humans following interferon therapy. Nature 282:417–419, 1979
Santoli D, Trinchieri G, Koprowski H: Cell mediated cytotoxicity against virus-infected target cells in humans. II. Interferon induction and activation of natural killer cells. J Immunol 121:532–538, 1978
Bakacs T, Gergery P, Klein E: Characterization of cytotoxic human lymphocyte subpopulations. The role of Fc-receptor carrying cells. Cell Immunol 32:317–328, 1977
Santoli D, Trinchieri G, Moretta L, Zmijewski CM, Kopvowski H: Spontaneous cell-mediated cytotoxicity in humans. Distribution and characterization of the effector cell. Clin Exp Immunol 33:309–318, 1978
Cooper SM, Hirsen DJ, Friou GL: Spontaneous cell-mediated cytotoxicity against chang cells by non-adherent, non-thymus derived, Fc-receptor-bearing lymphocytes. Cell Immunol 32:135–145, 1977
West WH, Cannon GB, Kay D, Bonnard GD, Herberman RB: Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: Characterization of effector cells. J Immunol 118:335–361, 1977
Matsubara S, Suzuki F, Ishida N: Induction of immune interferon in mice treated with a bacterial immunopotentiator, OK-432. Cancer Immunol Immunother 6:41–45, 1979
Matsubara S, Suzuki M, Ishida N: Impaired induction of type II interferon in tumor-bearing mice. Cancer Res 40:873–876, 1980
Misuno D, Taketani K, Ishida N: Host Defense Mechanism (IV). Tokyo, (eds): Tokyo University Press, 1981, in press
Wakasugi H, Oshimi K, Kasahara T, Miyata M, Morioka Y:In vitro augmentation of human natural killer (NK) cell activity by a streptococcal preparation OK-432 and its extracts, protein M and polysaccharides. Clin Immunol, 1981, in press (Jp.)
Kurokawa T, Hattori T, Furue H: Clinical experiences with the streptococcal anticancer preparation, OK-432 (NSC-B 116209). Cancer Chemother Rep 1 56:211–220, 1972
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wakasugi, H., Oshimi, K., Miyata, M. et al. Augmentation of natural killer (NK) cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors. J Clin Immunol 1, 154–162 (1981). https://doi.org/10.1007/BF00922757
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00922757